Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 6/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL766118 | 0.88 | RBP4 (0.43) | RBP4KDM4EALDH1A1LMNAGAA | |
| SCHEMBL766203 | 0.87 | RBP4 (0.56) | RBP4KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL766126 | 0.86 | RBP4 (0.41) | RBP4ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL766213 | 0.85 | RBP4 (0.40) | RBP4NOTUMKDM4EALDH1A1LMNA | |
| SCHEMBL766232 | 0.84 | RBP4 (0.40) | RBP4ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL766123 | 0.79 | RBP4 (0.66) | RBP4ALDH1A1LMNAMAPK1MEN1 | |
| SCHEMBL30227034 | 0.79 | RBP4 (0.66) | RBP4ALDH1A1LMNAMAPK1MEN1 | |
| SCHEMBL630560 | 0.75 | SLC6A9 (0.36) | RBP4NOTUMKDM4EALDH1A1LMNA | |
| SCHEMBL766166 | 0.72 | RBP4 (0.74) | RBP4ALDH1A1LMNASMN1; SMN2MAPK1 | |
| SCHEMBL630561 | 0.70 | PKM (0.53) | RBP4KDM4EALDH1A1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | RBP4, RBP1, FABP4 | RBP4 1/4885NOTUM 2302/4885KDM4E 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.